A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression
Phase: Phase III clinical trials
Principal Investigator: Dott. Lo Russo Giuseppe
Main Facility: Oncologia Medica Toraco-Polmonare
Drug: Ivonescimab (SMT112)
Pathologies: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
This is a global Phase 3 clinical trial designed to evaluate the safety and efficacy of a new investigational immunotherapy, ivonescimab, compared with pembrolizumab, the current standard first-line treatment for this patient population.
The study is intended for patients with metastatic non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for metastatic disease, whose tumors demonstrate high PD-L1 expression, and who do not harbor activating genetic mutations. Participants will be randomly assigned (1:1 randomization) to one of two treatment arms to directly compare the investigational drug with the current standard therapy.
Arm A (Investigational Arm): ivonescimab administered as monotherapy, a novel immunotherapeutic antibody designed to enhance the body's immune response against cancer through a dual mechanism of action.
Arm B (Control Arm): pembrolizumab administered as monotherapy, which represents the current standard first-line treatment for patients with metastatic NSCLC and high PD-L1 expression.
Last update: 16/07/2026